Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer
Clinical trial NCT04213937 · UNKNOWN
Trial details
- NCT number
- NCT04213937
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-01-31
- Primary completion
- 2021-07-31
- Enrollment
- 386
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.